Enveric Biosciences recently announced that it has signed a definitive agreement to acquire MagicMed Industries, a pharmaceutical drug discovery and development platform focused on new-generation psychedelic molecular compounds and derivatives.With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules. Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and serve unmet needs across multiple indications including oncology and CNS, such as PTSD. Upon closing, Dr. Joseph Tucker will be appointed Enveric Biosciences CEO and David Johnson as Executive Chairman.
#EnvericBiosciences #Cannabinoids #Psychedelics
View original source video by clicking here
After a quick push to have its first meeting on October 5, 2021, New York’s Cannabis Control Board (CCB) has already scheduled its second meeting